Papyrus Therapeutics

Papyrus Therapeutics is pioneering a novel therapeutic modality: protein replacement of tumor suppressors, a historically 'undruggable' target class. Its lead program, PYTX-004, is an OPCML-Fc fusion protein that selectively deactivates multiple receptor tyrosine kinases (RTKs) to collapse cancer signaling pathways, showing potent monotherapy and combination efficacy in preclinical models. The company is IND-enabling for ovarian cancer, with a strong IP position and a leadership team with deep oncology and drug development experience. Papyrus aims to create an entirely new category of cancer therapeutics with a potentially favorable safety profile.

Protein replacement platform for extracellular tumor suppressor proteins, specifically targeting the OPCML 'anti-scaffold' mechanism to selectively bind, deactivate, and degrade multiple activated receptor tyrosine kinases (RTKs).

Papyrus operates in a white space with no direct competitors developing protein replacement tumor suppressor therapies. Indirectly, it competes with all targeted therapies (TKIs, mAbs) against its target RTKs (e.g., HER2, AXL, MET inhibitors), but its unique mechanism of multi-RTK network inhibition via native biology is a key differentiator.